tirzepatide injection site arm Tirzepatide-Induced Reaction Arm Injection Sites for Tirzepatide:

However, it is noteworthy that a similar proportion of patients in both groups achieved a clinically significant total body weight loss of 5% or more and 10% or more at 12 months, which indicates the efficacy of this medication for both groups of patients. Researchers performed a retrospective cohort study with data from 305 adults with overweight or obesity who received once-weekly subcutaneous semaglutide (Wegovy, Novo Nordisk) at a Mayo Clinic center from 2021 to Jan

Int J Diabetes Endocrinol

This trial helped redefine expectations for pharmacologic obesity treatment and provided a benchmark against which newer multi-receptor therapies are often compared

Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G